Polygalasaponin XXXII

Polygalasaponin XXXII 是一种具有口服活性的认知增强剂,可促进 ERK、CREB、Synapsin I 以及 TrkB 的磷酸化,增强基础突触传递,减轻 Scopolamine (MS-P46812) 诱导的认知损伤,改善海马依赖性学习与记忆能力,并可用于认知功能障碍的相关研究。
产品编号: MS-Z29356 CAS No.: 176182-04-0 分子式: C79H118O38 分子量: 1675.76
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Polygalasaponin XXXII 是一种具有口服活性的认知增强剂,可促进 ERK、CREB、Synapsin I 以及 TrkB 的磷酸化,增强基础突触传递,减轻 Scopolamine (MS-P46812) 诱导的认知损伤,改善海马依赖性学习与记忆能力,并可用于认知功能障碍的相关研究。

生物实验数据

生物活性 Polygalasaponin XXXII is an orally active cognitive enhancer that promotes the phosphorylation of ERK, CREB, Synapsin I, and TrkB, enhances basal synaptic transmission, attenuates Scopolamine (MS-P46812)-induced cognitive impairment, improves hippocampus-dependent learning and memory, and can be used in research related to cognitive dysfunction.
IC50 & Target

TrkB

 

体外研究
(In Vitro)

Polygalasaponin XXXII (1 μM; 4 min) 可快速激活原代大鼠海马神经元 (5 分化日龄) 中 ERK、CREB 和突触蛋白 I 的磷酸化。
Polygalasaponin XXXII 可保护 PC12 细胞免受血清缺乏诱导的损伤。
Polygalasaponin XXXII 可保护 PC12 细胞免受 Glutamate (MS-R18116) 诱导的神经毒性损伤。

体内研究
(In Vivo)

Polygalasaponin XXXII (0.125-2 mg/kg;口服;每日一次;连续 16 天) 可显著改善 Scopolamine (MS-P46812) 诱导的小鼠认知障碍,其中 2 mg/kg 剂量产生的分子和行为学效应最为显著。
Polygalasaponin XXXII (400 μM; 侧脑室注射;单次) 可显著增强麻醉大鼠齿状回的基础突触传递并诱导长时程增强。
Polygalasaponin XXXII (0.125-2 mg/kg;口服;每日一次;连续 19 天) 可改善 Scopolamine (MS-P46812) 诱导的小鼠认知障碍,其中 0.5 mg/kg 和 2 mg/kg 剂量能显著增强海马区 TrkB 的磷酸化水平。
Polygalasaponin XXXII (400 μM 溶液 5 μL;侧脑室注射;单次) 可显著增强大鼠海马区 LTP,其 PS 幅值最高可达基线水平的 378%。

Animal Model: C57BL/6J (male, 8 weeks old, 18-20 g, scopolamine-induced amnesia)
Dosage: 0.125 mg/kg; 0.5 mg/kg; 2 mg/kg
Administration: p.o.; daily; 16 days
Result: Increased swimming time in the target quadrant during probe trial significantly compared to scopolamine model group.
Shortened scopolamine-prolonged escape latency significantly at 0.125 mg/kg and 2 mg/kg doses; showed a trend toward shorter latency at 0.5 mg/kg dose (P=0.053).
Increased hippocampal ERK phosphorylation significantly compared to both control and model groups at all doses.
Increased hippocampal CREB phosphorylation significantly compared to both control and model groups at 0.5 mg/kg and 2 mg/kg doses; significantly increased CREB phosphorylation compared to model group at 0.125 mg/kg dose.
Reversed scopolamine-induced attenuation of synapsin I phosphorylation significantly at 2 mg/kg dose.
Increased hippocampal BDNF levels significantly compared to model group at all doses; increased BDNF levels compared to control group at 2 mg/kg dose.
Animal Model: Wistar (male, 3 months old, 230-260 g)
Dosage: 1 μmol/L
Administration: i.c.v.; single dose
Result: Increased population spike amplitude to 162% of baseline within 5 min of administration.
Reached population spike amplitudes of 172%, 215%, and 254% of baseline at 10, 30, and 60 min post-administration, respectively.
Induced long-term potentiation in the hippocampal dentate gyrus, as shown by sustained increase of over 30% above baseline for more than 30 min.
Animal Model: C57BL/6J (male, 18-20 g)
Dosage: 5 mg/kg·d-1; 20 mg/kg·d-1
Administration: p.o.; daily; 13 days
Result: Significantly reversed scopolamine-induced increases in channel water maze latency time and error numbers (5 mg/kg dose only).
Demonstrated no significant efficacy relative to the model group (20 mg/kg dose only).
Animal Model: Wistar (male, 3 months old, 230-260 g)
Dosage: 5 μL of 400 μmol/L solution (final brain concentration of 1 μmol/L)
Administration: i.c.v.; single injection
Result: Significantly enhanced HFS-induced LTP compared to the control group.
Increased population spike (PS) amplitudes to 310% within 20 minutes post-injection, and reached 340%, 378%, and 366% at 40, 50, and 55 minutes post-injection, respectively.

化学信息

分子量 1675.76
分子式 C79H118O38
CAS No. 176182-04-0

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础